UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: Results of the French STIC prospective study

Radiotherapy and oncology, 2012-06, Vol.103 (3), p.305-313

2012

Volltextzugriff (PDF)

Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families

Genetics in medicine, 2018-12, Vol.20 (12), p.1677-1686

2018

Volltextzugriff (PDF)

Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Cancers, 2023-03, Vol.15 (6), p.1742

2023

Volltextzugriff (PDF)

Comparison of COBAS 4800 KRAS, TaqMan PCR and High Resolution Melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas

Virchows Archiv : an international journal of pathology, 2013-03, Vol.462 (3), p.329-335

2013

Volltextzugriff (PDF)

Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses

European urology, 2021-02, Vol.79 (2), p.214-221

2021

Volltextzugriff (PDF)

Biological evaluation of the effect of sugammadex on hemostasis and bleeding

Korean Journal of Anesthesiology, 2015, 68(1), , pp.17-21

2015

Volltextzugriff (PDF)

Reply to S. Zeng et al

Journal of clinical oncology, 2022-09, Vol.40 (26), p.3094-3095

2022

Volltextzugriff (PDF)

Outcomes according to histological variants of urothelial carcinoma after neoadjuvant chemotherapy in the GETUG-AFU V05 VESPER trial

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.533-533

2022

Volltextzugriff (PDF)

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial

Journal of clinical oncology, 2022-06, Vol.40 (18), p.2013-2022

2022

Volltextzugriff (PDF)

Perioperative chemotherapy in bladder cancer: the more cisplatin, the best survival?

World journal of urology, 2024-03, Vol.42 (1), p.140-140, Article 140

2024

Volltextzugriff (PDF)

Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial

The Journal of urology, 2024-04, Vol.211 (4), p.564-574

2024

Volltextzugriff (PDF)

Optimization of routine KRAS mutation PCR‐based testing procedure for rational individualized first‐line‐targeted therapy selection in metastatic colorectal cancer

Cancer medicine (Malden, MA), 2013-02, Vol.2 (1), p.11-20

2013

Volltextzugriff (PDF)

Vergleichende verhaltensbeobachtung bei männlichen chirurgisch kastrierten, immunokastrierten und unkastrierten mastschweinen

Harter, Valentin

2017

Volltextzugriff (PDF)

Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial

Journal of clinical oncology, 2023-06, Vol.41 (17_suppl), p.LBA4507-LBA4507

2023

Volltextzugriff (PDF)

Reply to S. Zeng et al

Journal of clinical oncology, 2022-06, p.JCO2201031

2022

Volltextzugriff (PDF)

SPiP: Splicing Prediction Pipeline, a machine learning tool for massive detection of exonic and intronic variant effects on mRNA splicing

Human mutation, 2022-12, Vol.43 (12), p.2308-2323

2022

Volltextzugriff (PDF)

Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study

The lancet oncology, 2024-02, Vol.25 (2), p.255-264

2024

Volltextzugriff (PDF)

Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.437-437

2020

Volltextzugriff (PDF)

350 GREAT: a unique cohort of 1500 advanced ovarian cancer (AOC) patients treated in real life with prospective biomarkers including tumor BRCA and HRD, and tumor collection, a GINECO study

International journal of gynecological cancer, 2024-03, Vol.34 (Suppl 1), p.A319-A319

2024

Volltextzugriff (PDF)

SpliceLauncher: a tool for detection, annotation and relative quantification of alternative junctions from RNAseq data

Bioinformatics, 2020-03, Vol.36 (5), p.1634-1636

2020

Volltextzugriff (PDF)

Detecting splicing patterns in genes involved in hereditary breast and ovarian cancer

European journal of human genetics : EJHG, 2017-10, Vol.25 (10), p.1147-1154

2017

Volltextzugriff (PDF)

Age Estimation in Living Adults using 3D Volume Rendered CT Images of the Sternal Plastron and Lower Chest

Journal of forensic sciences, 2016-01, Vol.61 (1), p.127-133

2016

Volltextzugriff (PDF)

Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: Correlation with clinicopathological criteria

Oncology reports, 2013-03, Vol.29 (3), p.1043-1052

2013

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(35)
Dissertationen
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: Results of the French STIC prospective study

Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families

ORGAVADS: establishment of tumor organoids from head and neck squamous cell carcinoma to assess their response to innovative therapies

Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Comparison of COBAS 4800 KRAS, TaqMan PCR and High Resolution Melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas

Biological evaluation of the effect of sugammadex on hemostasis and bleeding

Reply to S. Zeng et al

Outcomes according to histological variants of urothelial carcinoma after neoadjuvant chemotherapy in the GETUG-AFU V05 VESPER trial

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial

Perioperative chemotherapy in bladder cancer: the more cisplatin, the best survival?

Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial

Optimization of routine KRAS mutation PCR‐based testing procedure for rational individualized first‐line‐targeted therapy selection in metastatic colorectal cancer

Vergleichende verhaltensbeobachtung bei männlichen chirurgisch kastrierten, immunokastrierten und unkastrierten mastschweinen

Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial

Reply to S. Zeng et al

SPiP: Splicing Prediction Pipeline, a machine learning tool for massive detection of exonic and intronic variant effects on mRNA splicing

Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study

350 GREAT: a unique cohort of 1500 advanced ovarian cancer (AOC) patients treated in real life with prospective biomarkers including tumor BRCA and HRD, and tumor collection, a GINECO study

SpliceLauncher: a tool for detection, annotation and relative quantification of alternative junctions from RNAseq data

Detecting splicing patterns in genes involved in hereditary breast and ovarian cancer

Age Estimation in Living Adults using 3D Volume Rendered CT Images of the Sternal Plastron and Lower Chest

The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer

Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: Correlation with clinicopathological criteria

Suchergebnisse filtern